Key facts
- It has raised $8.6M; the latest was Later Stage VC ($5.4M) in Aug 2025.
- Notable investors include IMM Investment, Korea Technology Finance, Lotte Ventures, IBK Securities, JB Investment (Private Equity) — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Abio Materials
- ·The full record, as it builds
Funding rounds
No funding rounds for Abio Materials are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Abio Materials
Developer of bioactive cosmetic and medical products designed to utilize exosome-based compounds for regenerative applications. The company offers formulations derived from plant, human, and microbial exosomes that support cell signaling, inflammation reduction, and collagen synthesis, enabling skincare and medical device manufacturers to create clinically validated products that promote tissue regeneration, enhance skin health, and deliver targeted therapeutic benefits.
- Sector
- Healthcare
- HQ
- Yongin, South Korea
- Founded
- 2020
- Employees
- 69
- Website
- a-bio.co.kr/
- Ownership
- Privately Held (backing)
Abio Materials doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abio Materials shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abio Materials in its N-PORT filings yet. We sweep new filings monthly.